Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy.
Matthew GreenhawtSayantani B SindherJulie WangMichael O'SullivanGeorge du ToitEdwin H KimDeborah AlbrightSara AnvariNicolette ArendsPeter D ArkwrightPhilippe BéginKatharina BlumchenThierry BourrierTerri Brown-WhitehornHeather CassellEdmond S ChanChristina E CiaccioAntoine DeschildreAmandine Divaret-ChauveauStacy L DorrisMorna J DorseyThomas EiweggerMichel Erlewyn-LajeunesseDavid M FleischerLara S FordMaria Garcia-LloretLisa Giovannini-ChamiJonathan O HourihaneNicola JayStacie M JonesLeigh Ann KernsKirsten M KloepferStephanie LeonardGuillaume LezmiJay A LiebermanJeanne LomasMelanie MakhijaChristopher ParrishJane PeakeKirsten P PerrettDaniel PetroniWolfgang PfütznerJacqueline A PongracicPatrick QuinnRachel G RobisonGeorgiana SandersLynda SchneiderHemant P SharmaJuan TrujilloPaul J TurnerKatherine TuttleJulia E M UptonPooja VarshneyBrian P VickeryChristian VogelbergBrynn WainsteinRobert A WoodKatharine J BeeDianne E CampbellTodd D GreenRihab RouissiAurélie PeillonHenry T BahnsonTimothée BoisHugh A SampsonA Wesley BurksPublished in: The New England journal of medicine (2023)
In this trial involving children 1 to 3 years of age with peanut allergy, epicutaneous immunotherapy for 12 months was superior to placebo in desensitizing children to peanuts and increasing the peanut dose that triggered allergic symptoms. (Funded by DBV Technologies; EPITOPE ClinicalTrials.gov number, NCT03211247.).